Provided by Tiger Trade Technology Pte. Ltd.

Candel Therapeutics, Inc.

10.44
-0.4400-4.04%
Volume:1.27M
Turnover:13.48M
Market Cap:798.85M
PE:-7.26
High:11.25
Open:11.02
Low:10.37
Close:10.88
52wk High:14.00
52wk Low:4.35
Shares:76.52M
Float Shares:60.06M
Volume Ratio:1.35
T/O Rate:2.11%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.4390
EPS(LYR):-0.7210
ROE:-81.84%
ROA:-28.64%
PB:6.33
PE(LYR):-14.48

Loading ...

Candel Therapeutics grants inducement stock options for 63,000 shares at $8.3 each

Reuters
·
Jun 02

Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire
·
Jun 02

Bank of America Securities Remains a Hold on Candel Therapeutics (CADL)

TIPRANKS
·
Jun 01

Candel Therapeutics price target raised to $9 from $7 at BofA

TIPRANKS
·
May 19

Candel Therapeutics Highlights Phase 3 Prostate Cancer Data

TIPRANKS
·
May 16

Candel says CAN-2409 cuts prostate cancer recurrence risk 39% in Phase 3 follow-up

Reuters
·
May 16

Candel Therapeutics Reports Extended Clinical Benefit Over Multiple Clinical Endpoints in Patients From Phase 3 Trial of Aglatimagene Besadenovec (Can-2409) in Localized Prostate Cancer Under Prolonged Follow-up at Aua 2026 Annual Meeting

THOMSON REUTERS
·
May 16

Candel Therapeutics Reports Extended Clinical Benefit Over Multiple Clinical Endpoints in Patients from Phase 3 Trial of Aglatimagene Besadenovec (CAN-2409) in Localized Prostate Cancer Under Prolonged Follow-up at AUA 2026 Annual Meeting

GlobeNewswire
·
May 16

Canaccord Genuity Reaffirms Their Buy Rating on Candel Therapeutics (CADL)

TIPRANKS
·
May 15

Analysts Have Conflicting Sentiments on These Healthcare Companies: Humana (HUM), Pyxis Oncology (PYXS) and Candel Therapeutics (CADL)

TIPRANKS
·
May 15

Candel Therapeutics publishes corporate presentation on viral immunotherapies for solid tumors

Reuters
·
May 15

Candel Therapeutics Inc reports results for the quarter ended March 31 - Earnings Summary

Reuters
·
May 14

Candel Therapeutics reports Q1 loss

Reuters
·
May 14

Candel Therapeutics Q1 EPS $(0.14) Beats $(0.34) Estimate

Benzinga Earnings
·
May 14

BRIEF-Candel Therapeutics Q1 Net Income USD -8.861 Million

Reuters
·
May 14

Candel Therapeutics Q1 Operating Expenses USD 16.284 Million

THOMSON REUTERS
·
May 14

Press Release: Candel Therapeutics Reports First Quarter 2026 Financial Results and Recent Corporate Highlights

Dow Jones
·
May 14

Candel Therapeutics CEO presents at Stifel Virtual Targeted Oncology Forum

Reuters
·
May 13

Candel Therapeutics to Present at Upcoming Investor Conferences

GlobeNewswire
·
May 13

Candel Therapeutics Inc expected to post a loss of 32 cents a share - Earnings Preview

Reuters
·
May 08